RS-102221 is a drug developed by Hoffmann–La Roche, which was one of the first compounds discovered that acts as a potent and selective antagonist at...
6 KB (410 words) - 20:48, 5 April 2024
Fontana DJ, Trinh J, Rocha CL, Dawson MW, Flippin LA, Eglen RM (1997). "RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist". Neuropharmacology...
105 KB (10,013 words) - 07:55, 6 July 2024
(methiothepin) Nefazodone Pirenperone Pizotifen Propranolol Ritanserin RS-102221 S-14671 SB-200646 SB-206553 SB-221284 SB-228357 SB-242084 SB-243213 SDZ...
11 KB (954 words) - 09:58, 10 March 2024
(methiothepin) Nefazodone Pirenperone Pizotifen Propranolol Ritanserin RS-102221 S-14671 SB-200646 SB-206553 SB-221284 SB-228357 SB-242084 SB-243213 SDZ...
129 KB (13,890 words) - 08:46, 17 July 2024
Whitehouse Station, New Jersey: Merck. p. 1419. ISBN 978-0-911910-13-1. Gable RS (2004). "Comparison of acute lethal toxicity of commonly abused psychoactive...
142 KB (14,883 words) - 10:19, 22 July 2024
(methiothepin) Nefazodone Pirenperone Pizotifen Propranolol Ritanserin RS-102221 S-14671 SB-200646 SB-206553 SB-221284 SB-228357 SB-242084 SB-243213 SDZ...
34 KB (3,154 words) - 19:29, 13 July 2024
(methiothepin) Nefazodone Pirenperone Pizotifen Propranolol Ritanserin RS-102221 S-14671 SB-200646 SB-206553 SB-221284 SB-228357 SB-242084 SB-243213 SDZ...
105 KB (9,711 words) - 08:31, 21 July 2024
(methiothepin) Nefazodone Pirenperone Pizotifen Propranolol Ritanserin RS-102221 S-14671 SB-200646 SB-206553 SB-221284 SB-228357 SB-242084 SB-243213 SDZ...
22 KB (1,689 words) - 12:35, 14 July 2024
(methiothepin) Nefazodone Pirenperone Pizotifen Propranolol Ritanserin RS-102221 S-14671 SB-200646 SB-206553 SB-221284 SB-228357 SB-242084 SB-243213 SDZ...
11 KB (669 words) - 06:33, 20 February 2024
impairments, or simply not effective in the clinical populations tested. Marin RS, Wilkosz PA (2005). "Disorders of diminished motivation". J Head Trauma Rehabil...
118 KB (11,081 words) - 15:35, 19 July 2024